Idexx Beats Estimates, Raises Full-Year Outlook
Veterinary clinics and diagnostics buyers see steady testing demand as Idexx's results top analyst forecasts.
Updated on Nov. 2, 2026 in Economic Indicators
Idexx Laboratories reported third-quarter net income of $317.1 million, or $4.01 per share, and revenue of $1.21 billion, both ahead of analyst estimates. The veterinary diagnostics company also raised its full-year outlook, with earnings expected at $14.96 to $15.16 per share.
Why it matters
Beating analyst forecasts on both earnings and revenue signals steady demand for animal health testing, a segment that sits within the broader pet-care and veterinary economy. For operators in veterinary practices and diagnostics supply, the results suggest spending on in-clinic testing remains firm.
Idexx reported third-quarter net income of $317.1 million, or $4.01 per share, and adjusted earnings of $3.98 per share, above the analyst average of $3.71. Revenue reached $1.21 billion against an analyst estimate of $1.19 billion, and the company now expects full-year revenue of $4.74 billion to $4.77 billion.
The players
Idexx Laboratories
A Westbrook, Maine-based maker of veterinary diagnostic tests and laboratory instruments that sells to clinics and reference labs worldwide.
The details
Idexx's adjusted earnings and revenue both surpassed what analysts had projected, which is the mechanism behind the stock-relevant headline. The company's full-year guidance of $14.96 to $15.16 per share in earnings and $4.74 billion to $4.77 billion in revenue frames how it expects the rest of the year to unfold. Because these are company projections, they carry the usual uncertainty of forward-looking estimates.
Timeline
Idexx reported third-quarter results on November 2, 2026.
Market Landscape
Results above consensus estimates are measured against the forecasts analysts publish before each report, so beats and misses are read relative to those expectations rather than to prior-year figures. Idexx's raised full-year outlook places its performance within a broader veterinary diagnostics market that reports through the same quarterly cycle.
Operators in veterinary practices should expect diagnostic equipment and testing costs to remain a meaningful line item as demand holds steady. Suppliers and clinics may want to review purchasing and pricing terms in light of the company's raised full-year guidance.
The takeaway
Idexx's results show demand for veterinary diagnostics holding up above analyst expectations, a useful signal for operators tracking in-clinic testing spend. Watch the next quarterly report to see whether the raised full-year outlook is sustained.
Further reading
For broader context on how company results feed into national measures, see Economic Indicators across the United States economy.
Source note: This article includes information reported by WTOP.
